SUPN - CIK 0001356576
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported net income of -$38.60M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$38.60M | -152.2% |
| FY 2024 | $73.90M | +5584.6% |
| FY 2023 | $1.30M | -97.9% |
| FY 2022 | $60.70M | +13.7% |
| FY 2021 | $53.40M | -57.9% |
| FY 2020 | $126.95M | +12.3% |
| FY 2019 | $113.06M | +1.9% |
| FY 2018 | $110.99M | +93.8% |
| FY 2017 |
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported net income of -$38.60M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, SUPERNUS PHARMACEUTICALS, INC.'s net income declined from $53.81M to -$38.60M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $57.28M |
| -37.2% |
| FY 2016 | $91.22M | +554.2% |
| FY 2015 | $13.94M | +227.6% |
| FY 2014 | -$10.93M | +88.2% |
| FY 2013 | -$92.27M | -99.4% |
| FY 2012 | -$46.28M | -186.0% |
| FY 2011 | $53.81M | - |